Tratamento da Hipertensão Arterial Sistêmica Resistente

Procardiol 01/2011; 6:63-96.

ABSTRACT Leopoldo F. Saldanha, Aurélio Rotolo da Costa Araújo. Tratamento da Hipertensão Arterial Sistêmica resistente. Introdução. O objetivo do tratamento do paciente com hipertensão arterial sistêmica (HAS) é reduzir o risco cardio-vascular associado com a elevação da pressão arterial (PA). 1-3 A mortalidade por doença cardiovascular aumenta progressivamente, de forma linear, contínua e independente, em ambos os sexos e em todas as faixas etárias, com a elevação da PA a partir de 115/75mm Hg. 2,4 De acordo com diversas diretrizes, 5-7 inclusive a VI Diretrizes Brasileiras de Hipertensão, 8 as metas a serem obtidas no tratamento da HAS no adulto devem estar baseadas em características individuais e conforme o método empregado para aferição da PA. Pacientes com hipertensão arterial resistente (HAR) são aqueles cujas metas de PA não são atingidas, apesar do uso de três agentes anti-hipertensivos de diferentes classes, inclusive um diurético, ou cujas metas da PA somente são atingidas com o uso de quatro ou mais anti-hipertensivos. Quando se avalia a HAR, é importante afastar a possibilidade de pseudorresistência, resultante de fatores como medida inadequada da PA, efeito do avental branco e não adesão ao tratamento. Fatores contribuintes devem ser identificados e revertidos, incluindo obesidade, excesso de consumo de álcool e uso de subs-tâncias que interferem no controle da PA, especialmente anti-inflamatórios não hormonais (AINH), agentes simpaticomiméticos e estimulantes, além de anticoncepcionais.

Download full-text


Available from: Leopoldo Frederico Saldanha, Jul 05, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The renin-angiotensin system (RAS) has an important role in hypertension and the continuum of cardiovascular and kidney disease. The inhibition of this system, either with an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB), has been shown to be beneficial for cardiorenal protection. Dual blockade with an ACE inhibitor and ARB may have additional benefits due to the more complete inhibition of the system. Most published trials, including recent large studies and meta-analyses, have reported either limited or no additional benefit. Dual-blockade therapy seems to have some benefit on proteinuria and blood pressure reduction, and on morbidity and mortality in patients with heart failure, compared with monotherapy. The major issue arising from these published trials and meta-analyses is the increased frequency of dual therapy discontinuation and adverse effects on kidney function. There is a lack of hard end-point data for renal outcomes and long-term safety data in most published trials. Until the results of ongoing trials become available and as further safety data emerge, a wise approach would be to withhold use of ACE inhibitor and ARB combination therapy in general practice. When used in selected conditions, patients need to be closely monitored.
    American Journal of Kidney Diseases 03/2009; 53(2):332-45. DOI:10.1053/j.ajkd.2008.11.021 · 5.76 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Many studies have assessed short-term effects of weight loss on blood pressure, whereas little attention has been paid to long-term effects. We conducted a systematic review to evaluate the long-term effects of weight loss on hypertension outcome measures in adults using literature published from 1966 to 2001. All prospective studies and trials, performed on participants with body mass index of > or =28 kg/m2 with a follow-up of >2 years and weight changes recorded, were included. The data from these studies were used to model the long-term effects on blood pressure. Previous reviews on shorter-term studies indicate a 1:1 drop in blood pressure (mm Hg) with weight loss (kilograms). Our findings, based on studies with follow-up of > or =2 years, demonstrate blood pressure decreases less than this after weight loss. The surgical intervention studies exhibited huge weight losses with undramatic blood pressures changes. When surgical interventions are excluded, the models suggest that for 10 kg weight loss, decreases of 4.6 mm Hg and 6.0 mm Hg in diastolic and systolic blood pressure, respectively, may be expected, about half of that predicted from the short-term trials. Initial blood pressure, the length of follow-up, medication changes, and physiological restrictions may contribute to this reduced effect in the long-term studies. Extrapolation of short-term blood pressure changes with weight loss to the longer term is potentially misleading. The weight/hypertension relationship is complex and needs well-conducted studies with long-term follow-up to examine the effects of weight loss on hypertension outcomes.
    Hypertension 06/2005; 45(6):1035-41. DOI:10.1161/01.HYP.0000165680.59733.d4 · 7.63 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: About 5% of the US population is morbidly obese. This disease remains largely refractory to diet and drug therapy, but generally responds well to bariatric surgery. To determine the impact of bariatric surgery on weight loss, operative mortality outcome, and 4 obesity comorbidities (diabetes, hyperlipidemia, hypertension, and obstructive sleep apnea). Electronic literature search of MEDLINE, Current Contents, and the Cochrane Library databases plus manual reference checks of all articles on bariatric surgery published in the English language between 1990 and 2003. Two levels of screening were used on 2738 citations. A total of 136 fully extracted studies, which included 91 overlapping patient populations (kin studies), were included for a total of 22,094 patients. Nineteen percent of the patients were men and 72.6% were women, with a mean age of 39 years (range, 16-64 years). Sex was not reported for 1537 patients (8%). The baseline mean body mass index for 16 944 patients was 46.9 (range, 32.3-68.8). A random effects model was used in the meta-analysis. The mean (95% confidence interval) percentage of excess weight loss was 61.2% (58.1%-64.4%) for all patients; 47.5% (40.7%-54.2%) for patients who underwent gastric banding; 61.6% (56.7%-66.5%), gastric bypass; 68.2% (61.5%-74.8%), gastroplasty; and 70.1% (66.3%-73.9%), biliopancreatic diversion or duodenal switch. Operative mortality (< or =30 days) in the extracted studies was 0.1% for the purely restrictive procedures, 0.5% for gastric bypass, and 1.1% for biliopancreatic diversion or duodenal switch. Diabetes was completely resolved in 76.8% of patients and resolved or improved in 86.0%. Hyperlipidemia improved in 70% or more of patients. Hypertension was resolved in 61.7% of patients and resolved or improved in 78.5%. Obstructive sleep apnea was resolved in 85.7% of patients and was resolved or improved in 83.6% of patients. Effective weight loss was achieved in morbidly obese patients after undergoing bariatric surgery. A substantial majority of patients with diabetes, hyperlipidemia, hypertension, and obstructive sleep apnea experienced complete resolution or improvement.
    JAMA The Journal of the American Medical Association 11/2004; 292(14):1724-37. DOI:10.1001/jama.292.14.1724 · 30.39 Impact Factor